📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Differential Benefit from Fractionated Dose-Dense First-Line Chemotherapy for Epithelial Ovarian Cancer (EOC) According to Kelim-Evaluated Tumour Primary Chemosensitivity: Exploratory Analysis of Icon-8 Trial (2022)

First Author: You B

Attributed to: Developing Existing Healthcare Technologies to Deliver More Affordable and Effective Cancer Care funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.2139/ssrn.4043678

Publication URI: http://dx.doi.org/10.2139/ssrn.4043678

Type: Journal Article/Review

Parent Publication: SSRN Electronic Journal